The Ex-Banker Who Was Told She Didn't Look Like a Founder: How Romita Mazumdar Built a ₹650 Crore Skincare Challenger in Four Years—and Just Won Over a Japanese Beauty Giant

MUMBAI — May 25, 2026 — Before she built one of India's fastest-growing skincare brands, before she raised $30 million from a 80-year-old Japanese cosmetics conglomerate, before she stood on stage at retail conferences and was introduced as a founder to watch, Romita Mazumdar was asked a question she still remembers. She was at a team dinner, early in her career, surrounded by colleagues from the venture capital firm where she worked. Someone looked at her across the table and asked, in the casual, unthinking way that such questions are asked, whether she was an intern.

She was not an intern. She was a full-time investment professional, evaluating startups, making decisions about where capital should flow. But she was young. She was female. She did not look, to the person across the table, like someone who belonged in the room. The question was small, fleeting, and utterly forgettable—except that Mazumdar did not forget it. She filed it away, alongside the banking desk where she felt seen for the wrong reasons, the VC firm where she felt invisible, and the growing conviction that she was spending her career evaluating other people's businesses when she should be building her own.

In 2021, she quit. She founded Foxtale, a science-led skincare brand built around a single, uncompromising thesis: Indian skin needs Indian solutions, formulated with clinical rigour, sold at a price that made premium skincare accessible rather than aspirational. Four years later, Foxtale has served more than 1.5 million customers, built a portfolio of about 20 SKUs, and achieved a repeat purchase rate of nearly 50 percent. The company closed FY25 with approximately ₹350–400 crore in gross revenue and is on track to touch ₹650 crore in FY26—a growth rate of 150 percent year-on-year. It projects ₹800 crore for the current fiscal and has set its sights on crossing ₹1,000 crore within a few years. In January 2026, Japan's KOSÉ Corporation, one of the world's oldest and most respected beauty conglomerates, led a $30 million Series C round into the company—a strategic partnership aimed at scaling innovation and expanding the brand's global reach. The ex-banker who was once asked if she was an intern has built a business that a Japanese beauty giant now wants a piece of.

The Gap Nobody Had Closed

To understand what Foxtale has built, one must first understand the peculiar architecture of the Indian beauty market—and the gap that Mazumdar identified before almost anyone else.

The Indian skincare market has historically been defined by two poles. At one end, legacy ayurvedic brands—Vicco, Boroline, Lotus Herbals—that sold trust and tradition but offered little in the way of clinical efficacy or modern branding. At the other end, luxury imports—Estée Lauder, Clinique, Shiseido—that offered scientific formulations but at prices that placed them beyond the reach of the vast majority of Indian consumers. The middle ground—affordable, science-led, India-specific skincare—was almost entirely empty. The Indian consumer who wanted a vitamin C serum that was formulated for Indian skin, tested in Indian conditions, and priced for an Indian wallet had virtually no options. She could buy a generic drugstore product, or she could save up for a luxury import. There was nothing in between.

The D2C revolution of the late 2010s and early 2020s produced a wave of personal care brands—Mamaearth, The Derma Co., Plum, WOW Skin Science—that began to fill this gap. But most of these brands were built on a marketing-first, formulation-second model: identify a trending ingredient, source it from a contract manufacturer, and invest heavily in social media advertising. The products worked, more or less, but they were not built on a foundation of clinical research. The consumer who wanted genuinely science-backed skincare—products formulated with active ingredients at clinically effective concentrations, tested for efficacy and safety, designed with the same rigour as a pharmaceutical—was still underserved.

Mazumdar's insight was that this consumer was larger, savvier, and more demanding than the market had recognised. The same generation of Indian women who had embraced premium Indian brands in fashion, in jewellery, in personal care—who had been told their entire lives that quality came from elsewhere—was now ready for premium Indian skincare. But they would not be fooled by marketing. They read ingredient labels. They researched actives. They compared concentrations. They wanted efficacy, not just aesthetics. And they were willing to pay for it—not luxury prices, but a premium over mass-market alternatives—if the product delivered.

Foxtale was built to serve that consumer. The brand's formulations are developed in-house, with a focus on active ingredients—retinol, hyaluronic acid, niacinamide, vitamin C, peptides—at concentrations that are clinically validated. The products are tested for stability, safety, and efficacy. The brand operates a digital-first D2C model, with approximately 95 percent of revenue coming from online channels. Its own website contributes roughly 50 percent of total sales, followed by marketplaces such as Nykaa, Amazon, and Myntra. The company has been deliberate about not rushing into offline retail—a channel that would require a different cost structure, a different margin profile, and a different brand strategy than the one it has optimised for.

The repeat purchase rate tells the story of whether the products work. At nearly 50 percent, it suggests that the customer who tries Foxtale once tends to come back—not because she was retargeted by a Facebook ad, but because the product delivered on its promise. The company claims to have achieved 150 percent growth in FY25, supported by a growing base of repeat customers and an expanding portfolio of SKUs. The brand has launched in the bodycare category with a sub-brand called Hula Hoop, targeting what Mazumdar believes is a ₹150 crore opportunity within the next year. The SKU count remains deliberately lean—around 20 products—reflecting a conviction that depth of formulation matters more than breadth of catalogue.

The KOSÉ Validation

The single most significant external validation of Foxtale's approach arrived not from a venture capitalist, but from an 80-year-old Japanese beauty conglomerate. In January 2026, KOSÉ Corporation—one of Japan's largest cosmetics companies, with a portfolio that includes Decorté, Sekkisei, and Jill Stuart—led a $30 million Series C round into Foxtale, forming a strategic partnership aimed at scaling innovation and expanding the brand's reach.

The KOSÉ investment is significant for several reasons. First, it represents a bet by one of the world's most respected beauty conglomerates on an Indian D2C brand—a category that, until very recently, was dismissed by global beauty giants as a niche curiosity. Second, it provides Foxtale with access to KOSÉ's R&D capabilities, formulation expertise, and global distribution networks—resources that no Indian startup could build on its own. Third, it signals that the Indian beauty consumer—the same consumer who was once an afterthought for global brands, offered products formulated for Caucasian skin and marketed with Western aesthetics—is now significant enough to attract strategic investment from the companies that once ignored her.

Mazumdar has been deliberate about framing the KOSÉ partnership not as an exit, but as an acceleration. "This is not about selling the company," she told a business publication. "This is about building the company with a partner who understands the science of skincare at a level that few others do." The distinction matters. Foxtale is not a brand that was built to be acquired. It is a brand that was built to compete—with the legacy ayurvedic players at the value end, with the luxury imports at the premium end, and with the growing roster of D2C competitors in the middle. The KOSÉ partnership gives it ammunition that none of those competitors can match.

The broader context is an Indian beauty and personal care market that is among the fastest-growing in the world. The sector was valued at approximately $16 billion in 2018 and has been expanding at a compound annual rate that reflects rising disposable incomes, the normalisation of skincare among younger consumers, and the structural shift from unbranded to branded products. Within that market, the science-led, active-ingredient-based segment—the segment that Foxtale occupies—is growing faster than the overall category, driven by consumers who are trading up from basic moisturisers to targeted treatments. The KOSÉ investment is a bet that this segment will continue to outpace the broader market—and that Foxtale will capture a disproportionate share of its growth.

The Deliberate, Not Disruptive, Founder

Romita Mazumdar did not follow the script. The Indian startup ecosystem has a template for founders—one that Mazumdar, by her own admission, did not fit. She did not go to IIT. She did not work at McKinsey. She did not have a co-founder from her engineering college days or a viral product launch that broke the internet. She had a banking job, then a VC job, then a conviction that she wanted to build something of her own—and the self-awareness to know that she was not yet ready.

In a podcast conversation with Matrix Partners' Avnish Bajaj earlier this year, Mazumdar described the years before Foxtale with an unusual candour. There was the banking desk where she felt seen for the wrong reasons—valued for her presence rather than her insight. There was the VC firm where she felt invisible—her judgments dismissed, her authority questioned, her belonging contingent on looking and acting like the people around her. And there was the slow, difficult realisation that she could not build a company until she stopped seeking validation from people who would never give it.

"What does it mean to build for yourself, not for validation?" Bajaj asked her. The question, she said, was the right one—and the answer was something she had to learn, not something she already knew. "You either need self-belief, passion, or obsession," she said. "One of the three. A hundred percent. That's the bar."

The Foxtale founding story reflects that philosophy. Mazumdar did not launch with a splash. She launched with four products—a cleanser, a moisturiser, a serum, a sunscreen—that represented a complete, simple skincare routine. The formulations were developed over months of research, testing, and iteration. The branding was clean and understated, designed to communicate efficacy rather than glamour. The marketing was education-first: explain what hyaluronic acid does, explain what niacinamide is for, explain why retinol should be introduced gradually. The customer who bought a Foxtale product was not just buying a cream. She was buying an education—and the education built trust that the marketing alone could not.

The brand has remained disciplined about its portfolio. At roughly 20 SKUs, Foxtale is far smaller than most of its D2C competitors, some of which have expanded into dozens of categories in pursuit of growth. Mazumdar's argument is that depth matters more than breadth—that the brand's credibility rests on making each product genuinely effective, rather than filling every conceivable category with a generic formulation. The bodycare expansion through Hula Hoop is the first significant departure from this strategy, and even there, the approach is measured: enter a category that is adjacent to the core, develop products with the same clinical rigour, and let the brand's reputation do the distribution.

The Road to ₹1,000 Crore

Foxtale's financial trajectory is impressive by any standard, but it is not yet profitable. The company's net loss widened to approximately ₹73 crore in FY25, as cash burn increased with the growth in sales. The path to profitability is visible—the gross margins in skincare are healthy, the repeat purchase rate suggests that customer acquisition costs are being recovered over time, and the operating leverage of a digital-first model improves as revenue scales—but it is not yet closed. The $30 million Series C provides the runway to reach scale without the desperate fundraising that has defined the post-ZIRP era for many D2C brands.

The competitive landscape is intensifying. Mamaearth, the largest D2C personal care brand in India, is publicly listed and profitable, with revenue exceeding ₹2,300 crore. The Derma Co., owned by Honasa Consumer, targets the same active-ingredient segment as Foxtale, with the backing of a parent company that has deep pockets and a growing offline distribution network. Plum, WOW Skin Science, and a growing roster of D2C competitors are vying for the same consumer. The legacy players—L'Oréal, Unilever, P&G—are launching their own D2C brands, bringing decades of formulation expertise and massive marketing budgets to a market they once ignored.

Mazumdar's response to the competitive threat is to double down on what the competitors cannot easily replicate: formulation credibility. Most D2C skincare brands do not develop their own formulations. They source them from contract manufacturers, customise the packaging and the marketing, and compete on branding. Foxtale develops its own formulations in-house, with a team of cosmetic chemists and a commitment to clinical testing that is unusual for a startup of its size. The KOSÉ partnership deepens that advantage: access to the R&D infrastructure of a global beauty conglomerate is something that no Indian D2C competitor can match, and it creates a formulation moat that will widen over time.

The brand's distribution strategy is also evolving. Currently, approximately 95 percent of revenue comes from online channels—a concentration that is both a strength and a vulnerability. Online distribution gives Foxtale direct relationships with its customers, rich data on purchasing behaviour, and margins that are higher than offline retail. But it also limits the brand's reach to the roughly 200 million Indians who shop online. The remaining 1.2 billion—including the vast majority of consumers in Tier-2 and Tier-3 cities, where the offline retail infrastructure is dominant—are inaccessible through digital channels alone. Mazumdar has said the brand will expand offline when the time is right, but she has been deliberately vague about when that will be. The discipline is strategic. Offline expansion requires a different cost structure, and Foxtale is not yet ready to make that transition.

The Woman Who Didn't Look the Part

The most powerful thread in Mazumdar's story is not the revenue growth or the KOSÉ partnership. It is the question she was asked at the team dinner—and the answer she has spent the past several years building.

The Indian startup ecosystem has a visibility problem. Women founders receive a fraction of venture capital funding—the share going to female founders dropped from 11 percent to 2.5 percent between 2019 and 2025, according to data from WinPe, a nonprofit focused on gender diversity in private equity. The reasons are complex and structural, but one of them is simpler than the industry likes to admit: women founders often do not look like what investors expect founders to look like. They are asked different questions. They are held to different standards. They are mistaken for interns, assistants, and marketing managers at their own companies.

Mazumdar has been deliberate about not letting the question define her. "I don't spend much time thinking about it," she said in a recent interview. "The work is hard enough. Building a science-led skincare brand in India is hard enough. The regulatory pathway is hard enough. If you spend time thinking about what other people think about you, you will never get anything done." The statement is both a personal philosophy and a strategic insight. The brand that Mazumdar has built is, in its own way, a response to the question she was asked at the dinner table. It is a demonstration that the person who does not look the part can build the part—and build it better than the people who were never questioned.

The 1.5 million customers who have bought Foxtale products are not buying a founder's story. They are buying a vitamin C serum, a retinol cream, a hyaluronic acid moisturiser. But the story matters because it shapes the product. The same attention to detail—the refusal to accept shortcuts, the insistence on clinical rigour, the conviction that Indian consumers deserve better than they have been given—is visible in both. Mazumdar is not the founder she was supposed to be. She is the founder she decided to become. The $30 million from KOSÉ, the 150 percent growth, the ₹1,000 crore ambition—all of it flows from that decision. The woman who was asked if she was an intern is no longer answering the question. She is building the company that makes the question irrelevant.